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Overexpression of cancer stem cell marker Lgr5 in 
colorectal cancer patients and association with 
clinicopathological findings 
 
Abstract 
Background: To determine the expression of cancer stem cell marker Leucine-rich repeat-
containing G-protein coupled receptor 5 (Lgr5) in colorectal carcinoma samples compared 
to normal adjacent tissue and any possible association with clinicopathological findings. 
Methods: This study was performed on forty samples of cancerous colorectal tissues (case 
group) and their adjacent normal mucosa (control group) in Imam Khomeini Hospital 
(Sari, Mazandaran, Iran). Expression of Lgr5 in tissue sections was done by 
immunohistochemistry. Statistical analysis was carried out using SPSS software. 
Results: Forty colorectal cancer patients including 21 males (57.8±11.6 years) and 19 
females (58.4±12.77 years) were enrolled. Lgr5 was overexpressed in tumoral samples 
than normal adjacent tissues (77.5% vs 27.5%, p<0.001). Also, no association was found 
between primary tumor, regional lymph nodes, invasion, histological type, grade, distant 
metastasis and IHC results. Patients with low Lgr5 expression had a better survival rate 
than patients with high expression but this was not statistically significant (p=0.121). 
Conclusion: The higher immunoreactivity of Lgr5 in colorectal cancer tissues may 
indicate its role as a cancer stem cell marker in tumor carcinogenesis and patient’s survival 
however; Lgr5 is not associated with pathological prognostic variables. 
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Cancer has become a major health problem worldwide and along with obesity has 
been considered as a 21th-century epidemic (1). Colorectal cancer (CRC) is one of the 
commonest malignancies which ranks the third diagnosed cancer and the fourth cause of 
cancer related mortalities (2). CRC is noteworthy in several aspects including economic 
impact and financial burden on the healthcare system and a remarkable increase in 
mortality and incidence especially in young adults (3, 4). The emergence of treatment 
resistant cells, which is attributed to stem cells in tumor, is a critical barrier in cancer 
treatment that can eventually lead to failure in chemo-radiation therapy, recurrence and 
metastasis. Cancer stem cells (CSCs) were first described by Hope KJ et al (1977) in acute 
myeloid leukemia cell population Indeed, it is believed that cancerous tissue comprises of 
three cellular population similar to normal tissue: stem cells, proliferating and mature cells 
(5). These small subpopulations of tumoral cells share multiple features with normal stem 
cells including self-renewal and multi-potency abilities and are responsible for tumor 
initiation and transplantation, distant metastasis, tumor recurrence and drug resistance (6-
8). Leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5) also known as 
GPR49 or GPR67 is a member of G protein-coupled receptors (GPCRs), highly important 
transmembrane proteins which are involved in cellular signal transduction.  
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This multi-pass membrane protein is encoded by Lgr5 
gene located on 12q21.1. Lgr5 consists of an extracellular N-
terminal domain (containing leucine-rich repeats), 
transmembrane helices which pass membrane seven times 
and an intracellular N-terminal domain (9). Intestinal 
epithelium, to maintain integrity and homeostasis, is known 
to have a high regeneration rate which is guaranteed by the 
stem cells residing in the base of crypts (10). The 
accumulation of mutations in intestinal stem cells, the most 
notable in a tumor suppressor gene named adenomatous 
polyposis coli (APC), leads to over-expansion and 
proliferation of cells and is a key stage in the development of 
the pre-cancerous and tumoral lesions of the colon and 
rectum. Mutated APC gene results in over-activation of a 
signaling pathway named Wnt/β-catenin (11). Wnt/β-catenin 
is involved in different cellular functions including 
proliferation and migration accordingly is frequently 
dysregulated in cancers (12-14). In physiologic conditions 
Lgr5 acts to maintain intestinal homeostasis and cellular 
adhesion (15, 16). Also over-expression of Lgr5 will 
enhance Wnt/β-catenin (9, 17). Recently, researches have 
introduced Lgr5 as a potential adult cancer stem cell marker. 
Its oncogenic characteristics have been reported in various 
malignant conditions including cancers of cervix, breast, 
gastric, and colorectal which is responsible for cell 
proliferation, movement, invasion, drug resistance, and 
metastasis. Thus this study examined Lgr5 expression on 
CRC samples and any association with clinicopathological 
characteristics of tumor. 
 
 
Method 
Patients: Paraffin-embedded tissues obtained from 
colectomy were selected from 40 colorectal cancer patients 
who referred to Imam Khomeini Hospital Sari, Iran. 
Pathological features including tumor type, histological 
grade, stage, perineural and vascular invasion, TNM 
categories of AJCC/UICC staging system and demographic 
data were extracted. We used normal mucosa adjacent to the 
tumor as control. Subjects had no prior history of 
chemotherapy or radiotherapy. The study contents were 
approved by the hospital ethics committee. 
LGR5 Immunohistochemistry staining protocol: For 
immunohistochemical evaluations, formalin-fixed paraffin-
embedded (FFPE) tissue blocks extracted from tumor lesions 
were used. Staining was performed on 5 μm thick sections 
mounted on slides organosilane-coated. The slides were 
washed twice in xylene (to eliminate paraffin), then were 
immersed in pure alcohol three times, washed with running 
water and immediately subjected to distilled water. Antigen 
retrieval was performed using citrate (30 min at 99° C, PH 
6). After returning to the room temperature, slides were 
immersed for 10 minutes in 3% hydrogen peroxide. After 
returning to room temperature, slides were immersed in 
hydrogen peroxide 3% for 10 minutes. Afterwards they were 
incubated with rabbit polyclonal antibody to LGR5 (Biorbyt, 
Cambridge, UK) at 1: 200 and then washed with buffered 
saline solution. The next incubation was performed with a 
DAB-based chromogen solution for ten minutes in dark and 
samples were washed in distilled water. Positive 
immunohistochemical staining includes cases where the cells 
exhibited a brownish cytoplasm, irrespective of intensely. 
Five random fields at 400X magnification were determined 
for each sample. The scoring point was calculated as 
mentioned by Hou et al. (18) using sum of proportion score 
(0-25%=1, 26-50%=2, 51-75%=3, 76-100%=4) and intensity 
score (negative=0, mild=1+, moderate=2+ and strong=3+). 
This yielded a score ranging 1-7. The median expression 
score in tumor and adjacent samples was used to describe 
cut-off point. Therefore the scores ≥4 (median) were 
considered high expression and expression scores below 4 
were categorized in low IHC group.  
Statistical analyses were performed with SPSS software 
(Version 18). Chi-square and Fisher's exact test were applied 
for qualitative data and t-test was used to analyze 
quantitative data. Life table method was applied to calculate 
survival and survival Kaplan-Meier method and log rank test 
was used to compare survival in high and low Lgr5 
expression group. Results were considered as statistically 
significant if p-value was less than 0.05.   
  
 
Result 
Table 1 describes patient’s demographic and main 
clinical and pathological information according to their 
gender. As shown, there were no significant differences in 
the data of patients based on their gender. Each tumoral 
sample was examined by immunohistochemistry staining for 
Lgr5 expression compared to normal adjacent tissue. 
Cytoplasmic expression of Lgr5 was detected in all samples 
(including tumoral and non-tumoral). Expression levels 
based on the pathological findings are summarized in table 2.  
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Table 1: Clinicopathological findings based on patient's gender 
Gender  
Variable 
Male Female P-value 
Age, year (mean ±SD) 57.8±11.6 58.4±12.77 0.87 
Tumor grade, n (%) 
Well-differentiated 
Moderately differentiated  
poorly differentiated 
 
18 (85.7%) 
1 (4.8%) 
2 (9.5%) 
 
18 (94.7%) 
1 (5.3%) 
0 (0%) 
 
0.73 
Histological subtypes, n (%) 
Adenocarcinoma (conventional type) 
mucinous carcinoma 
 
19 (90.5%) 
2 (9.5%) 
 
16 (84.2%) 
3 (15.8%) 
 
0.65 
 
Stage, n (%) 
I 
II 
III 
IV 
 
1 (4.8%) 
10 (47.6) 
3 (14.3%) 
4 (19%) 
 
3 (15.8%) 
8 (42.1%) 
4 (21%) 
2 (10.5%) 
 
 
0.64 
T, n (%) 
T1, T2 
T3 
 
1 (4.8%) 
20 (95.2%) 
 
4 (21%) 
15 (79%) 
 
0.17 
 
N, n (%) 
Nx 
N0 
N1 
N2 
 
3 (14.3%) 
13 (61.9%) 
4 (19%) 
1 (4.8%) 
  
2 (10.5%) 
11 (58%) 
4 (21%) 
2 (10.5%) 
 
 
0.96 
 
Distant metastasis, n (%) (positive) 4 (19%)  2 (10.5% ) 0.66 
 
Table 2; Lgr5 expression in relation to clinicopathological data 
Variable  High Lgr5 expression 
Sum of IHC score ≥4)) 
Low Lgr5 expression  
Sum of IHC score<4)) 
P-value 
Samples n (%)  
CRC 
Normal adjacent tissue 
 
31 (73.8%) 
11 (26.2%) 
 
9 (23.7%) 
29 (76.3%) 
 
P< 0.001 
Patient, n (%)  
Male 
Female  
 
17 (54.8%) 
14 (45.2%)  
 
4 (44.5%) 
5 (55.5%) 
 
0.71 
Tumor grade, n (%) 
Well-differentiated 
Moderately differentiated  
Poorly differentiated 
 
28 (90.3%) 
2 (6.5%) 
1 (3.2%) 
 
8 (88.9%) 
0 (0%) 
1 (11.1%) 
 
 
0.66 
Perineural and vascular invasion, n (%) 4 (12.9%) 1 (11.1%) 1 
N, n (%) 
N0 
N1,N2 
 
19 (61.3%) 
8 (25.8%) 
 
5 (55.5%) 
3 (33.5%) 
 
0.68 
 
T, n (%) 
T1, T2  
T3 
 
4 (12.9%) 
27 (87.1%) 
 
1 (11.1%) 
8 (88.9%) 
 
1 
Stage, n (%) 
I 
II 
III 
IV 
 
3 (9.7%) 
14 (45.16%) 
4 (12.9%) 
6 (19.35%) 
 
1 (11.11) 
4 (44.5%) 
3 (33.3%) 
0 (0%) 
 
 
0.37 
Distant metastasis (positive), n (%) 6 (19.35%) 0 (0%) 0.30 
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Higher expression of Lgr5 was observed in tumoral 
samples when compared to normal adjacent tissues 
(P<0.001). There were no other statistically differences 
between expression categories and clinicopathological 
findings. In figure 1, the expression patterns of Lgr5 in both 
tumoral and non-tumoral samples are shown. Seven patients 
died due to CRC and all of them were in high Lgr5 
expression group (P=0.121). One, three and five year 
survival in high expression group was 100%, 81% and 75%, 
respectively. Survival examination of CRC patients based on 
Lgr5 expression is presented in figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: IHC study, (a) weak to moderately cytoplasmic Lgr5 
staining in normal colon tissue (x400), (b,c) moderately 
cytoplasmic staining in colon cancer cells ×100 and x400 
respectively; (d) strongly cytoplasmic staining in colon cancer 
cells (x100). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Kaplan-Meier curve for low and high 
expression of Lgr5 in colorectal cancer patients (P=0.121) 
Discussion 
The North of Iran has been reported as a region with high 
incidence of CRC. Although the incidence of this disease in 
Iran is low compared to Western countries, an increase in 
trend and incidence in younger Iranian people should be 
taken into consideration (19). It is worth mentioning that 
CRC is usually diagnosed at advanced stages with 
unfavorable prognosis in Iran (20) Therefore, identifying 
biomarkers that can be considered as potential therapeutic or 
diagnostic targets is of particular importance. We 
demonstrate a higher expression of Lgr5 in this tumor-
normal comparison study. In cervical cancer cell lines, Cao 
et al showed that Lgr5 overexpression results in the 
tumorsphere formation, drug resistance to cisplatin and 
invasion (21).  
An IHC study by Hou demonstrated LGR5 and β-catenin 
expression in 126 breast cancer patients. 46% of samples 
revealed high Lgr5 expression which was associated with 
lymph node metastasis, size of the tumor and triple negative 
status. Also, the higher simultaneous expression of Lgr5 and 
β-catenin resulted in shorter relapse-free survival and poor 
prognosis (18).  
There is a similar report in colon cancer where both mice 
model and patients with Lgr5 positive tumors had decreased 
survival rates (22).  However, the results are inconsistent 
regarding the oncogenic role of Lgr5 as in mice mammary 
stem cells, Lgr5 was not a necessary component for 
tumorigenesis (tumor initiation) and progression (23). It was 
reported that decreasing the expression level of Lgr5 via 
siRNAs, promotes clonogenic ability and tumorigenicity 
while its overexpression leads to an increase in cell-cell 
adhesion and lower motility and introduced Lgr5 as a wnt 
signaling pathway suppressor (24). Xiang-Shan Fan in an 
IHC study of 132 samples (comprising 12 normal colon 
mucosa, 18 adenomas and 102 colorectal cancer cases) 
showed a significantly higher expression of Lgr5 in 
cancerous tissues but similar to our observation, this 
expression was not associated with pathological 
characteristics like differentiation grade, TNM status, 
invasion or age of participants but a higher expression was 
determined in female subjects (25).  
In contrast vascular invasion, lymph node metastasis, and 
TNM stages were associated with elevated Lgr5 expression 
but no relation was found with CRC patient gender, age, 
tumor grade, and metastasis in the study conducted by He S 
et al. also the patients in low expression group had higher 
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survival rate (26). In gastric cancer tissues, contrary to the 
findings mentioned above, Lgr5 expression was lower in 
samples from patients when compared to normal gastric 
mucosa. TNM stage, gender, and invasion were not 
influenced by Lgr5 expression (27). Resistance to 
chemotherapy regimen is a critical issue in oncology and 
may assist cancer relapse and metastasis (28). Various 
studies have been conducted on the role of cancer stem cells 
in developing drug resistance. In fact, the inherent ability of 
CSCs to repair the damaged genome and self-renewal 
properties are responsible for the development of resistance 
to chemo-radiotherapy (29).  
In this regard, Hsu et al. observed the significant 
association between high Lgr5 expression in CRC patients 
and unfavorable response to 5-fluorouracil based treatment. 
Overexpression of Lgr5 was not only associated with chemo-
resistance but also with metastasis and cancer stage (30).  A 
systematic review and meta-analysis of 7 studies (4 from 
China, 2 from Japan, 1 from the USA) concerning the 
relationship between lgr5 and CRC survival, reported the 
association between higher Lgr5 expression and lower 
overall survival (OS). This was observed for OS in Asian 
studies and not the USA (31). We found that patients with 
higher Lgr5 expression had shorter survival than that in low 
expression group, however, this trend did not reach statistical 
significance which may be due to sample size.  
We declare that the present study has some limitations 
that should be addressed. We used non-tumoral tissues 
adjacent to tumor as control specimens. Although 
immunochemical studies use adjacent tissues frequently, 
there is some evidence of molecular and transcriptome 
alterations in them which may differ normal tissues (32, 33). 
A relatively small sample size is another limitation. Finally, 
we found overexpression of Lgr5 in CRC tissues and its 
impact on survival but no association regarding sex and 
pathological data. 
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